Highly Potent Fully Human Anti-VISTA Antibodies Efficiently Abrogate the Interaction of VISTA to Its Putative Receptors at Different pH
Thierry Guillaudeux, PhD, Chief Scientific Officer European Society for Medical Oncology (ESMO) Virtual Congress 2020 | December 9, 2020
Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies
Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies Seattle, WA -- (December 9, 2020) Kineta, Inc., a clinical stage biotechnology company focused o ...